Leonard Post PhD has more than 30 years of experience with all stages of drug development, from early discovery through FDA approval. He is currently Chief Scientific Officer at Vivace Therapeutics, an oncology drug discovery and development company. Previously he was Chief Scientific Officer of BioMarin Pharmaceuticals, Chief Scientific Officer and Co-Founder of LEAD Therapeutics, and Senior Vice President of Research and Development at Onyx Pharmaceuticals. He also held various positions at Parke-Davis and Upjohn.
Dr Post has a depth of experience with oncolytic viruses which began with his leading the adenovirus program at Onyx, and later when he served as a board member at BioVex and Viralytics. He currently is a member of the boards of directors at Vivace Therapeutics, Orphagen Pharmaceuticals, Fedora Pharmaceuticals, Cold Genesys, UniQure NV and Oxyrane. Dr Post has a Ph.D. in biochemistry and undertook postdoctoral work in virology, including early work on the genetic engineering of herpes simplex virus.
